In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.
Several cancer drug candidates are designed to kill tumor cells by attacking certain targets, but they work in other ways, researchers found.
A Penn team is adapting CAR-T cell therapy to target cardiac fibrosis, and they have promising early results in rodents.
Researchers are finding new strategies to treat pancreatic cancer by depriving tumor cells of key proteins they need to survive.
With a new, privately funded research center, Johns Hopkins is trying to jump-start psychedelic research that has been stymied since the 1970s.
A revised flavonoid could promote the regrowth of functional myelin in mice, scientists at the Oregon Health & Science University have shown.
UC San Diego bioengineers prolonged the function of gene circuits that can be used to produce and deliver cancer drugs.
A self-assembling peptide hydrogel developed by the New Jersey Institute of Technology improved neuronal survival in rats with traumatic brain injury.
When the gene-editing technology CRISPR-Cas9 to inhibit the gene FABP4 in mice, the animals lost 20% of their body weight.
Blocking the enzyme CDK7 could be a new way to overcome resistant prostate cancer, and one drug is already in trials.
